| Full text | |
| Author(s): |
Vivanco, Bruno C.
[1]
;
Viana, Jacqueline D.
[1]
;
Perez, Elisabeth C.
[2]
;
Konno, Fabiana T. C.
[2]
;
Guereschi, Marcia G.
[1]
;
Xander, Patricia
[3]
;
Keller, Alexandre C.
[1, 4]
;
Lopes, Jose D.
[3, 1]
Total Authors: 8
|
| Affiliation: | [1] Univ Fed Sao Paulo, Dept Microbiol Imunol & Parasitol, Sao Paulo - Brazil
[2] Univ Paulista, Sao Paulo - Brazil
[3] Univ Fed Sao Paulo, Dept Ciencias Biol, Sao Paulo - Brazil
[4] Univ Fed Sao Paulo, Dept Med, Sao Paulo - Brazil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | Immunobiology; v. 219, n. 11, p. 845-849, NOV 2014. |
| Web of Science Citations: | 2 |
| Abstract | |
Autologous vaccination with tumor-primed dendritic cells increases immune response against tumor, which seems to be improved in host absence of CCR5. Because B-1 lymphocytes modulate the activity of different immune cells, we decided to study their influence in the resistance against murine B16F10 melanoma in a CCR5 deprived environment. Adoptive transfer of peritoneal B-1 CCR5(+/+) lymphocytes to CCR5(-/-) animals inhibited the establishment of lung metastasis and melanoma cell growth, in comparison to saline-treated CCR5-/- mice. In loco cell analysis demonstrated that the adoptive transfer of B-1 CCR5(+/+) + lymphocytes to CCR5 deficient host was associated with a more intense influx of T CD8(+) to tumor site, indicating that the presence of CCR5(+/+) B-1 cells in the tumor environment induces the migration of T CD8 CCR5(-/-) cells to the implantation site. To corroborate this idea, CCR5(-/-) mice were injected with non B-1 peritoneal cells from wild type (WT) mice before B16F10 inoculation. In this regimen, CCR5(-/-) mice were not protected from tumor growth reinforcing the idea that, in host absence of CCR5, B-1 cells are essential to confer tumor resistance. This work indicates that, in the host absence of CCR5, naive B-1 cells may activate CD8T lymphocytes thereby promoting tumor resistance. Our results strongly suggest that autologous vaccination with B-1 lymphocytes in combination with CCR5 antagonists can be an alternative approach to tumor therapy. (C) 2014 Elsevier GmbH. All rights reserved. (AU) | |
| FAPESP's process: | 11/50256-6 - Celulas b-1: biologia, relacoes com outras celulas do sistema imune e participacao em diferentes modelos experimentais. |
| Grantee: | José Daniel Lopes |
| Support Opportunities: | Research Projects - Thematic Grants |